The melatonin analog 5-MCA-NAT increases endogenous dopamine levels by binding NRH: Quinone reductase enzyme in the developing chick retina

International Journal of Developmental Neuroscience

Volumn 38, Issue , 2014, Pages 119-126

  Sampaio, Lucia de Fatima Sobral ^a   Mesquita, Felipe Pantoja ^a   de Sousa, Paulo Robson Monteiro ^a   Silva, JerÔnimo Lameira ^a   Alves, Claudio Nahum ^a  

^a FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

5 MCA NAT; Benzo e pyrene; Dopamine; Melatonin receptors; NRH:quinone reductase; Retina

Indexed keywords

5 METHOXYCARBONYLAMINO N ACETYLTRYPTAMINE; BENZO[E]PYRENE; CYCLIC AMP; DOPAMINE; LUZINDOLE; MELATONIN; MELATONIN DERIVATIVE; MELATONIN RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESVERATROL; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BINDING SITE; CHICK; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MOLECULAR DOCKING; NONHUMAN; OXIDATION REDUCTION STATE; PROTEIN BINDING; PROTEIN FUNCTION; RETINA DEVELOPMENT; SYNAPTOGENESIS;

EID: 84907816017     PISSN: 07365748     EISSN: 1873474X     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2014.09.001     Document Type: Article

References (58)

1. Alarma-Estrany P., Crooke A., Pintor J. 5-MCA-NAT does not act through NQO2 to reduce intraocular pressure in New-Zealand white rabbit. J. Pineal Res. 2009, 47:201-209.
2. Arushanian É B. Universal therapeutic properties of melatonin. Klin. Med. (Mosk) 2013, 9:4-8.
3. Bouayed J., Desor F., Rammal H., Kiemer A.K., Tybl E., Schroeder H., Rychen G., Soulimani R. Effects of lactational exposure to benzo[alpha]pyrene (B[alpha]P) on postnatal neurodevelopment, neuronal receptor gene expression and behavior in mice. Toxicology 2009, 259:97-106.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
5. Brandies R., Yehuda S. The possible role of retinal dopaminergic system in visual performance. Neurosci. Biobehav. Rev 2008, 32:611-656.
6. Brown L.A., Khousbouei H., Goodwin J.S., Irvin-Wilson C.V., Ramesh A., Sheng L., McCallister M.M., Jiang G.C., Aschner M., Hood D.B. Down-regulation of early ionotrophic glutamate receptor subunit developmental expression as a mechanism for observed plasticity deficits following gestational exposure to benzo(a)pyrene. Neurotoxicology 2007, 28:965-978.
7. Buryanovskyy L., Yue F., Molly B., Yuliang M., Hsieh T., Wu J.M., Zhang Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004, 43:11417-11426.
8. Calamini B., Santarsiero B.D., Boutin J.A., Mesecar A.D. Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem. J. 2008, 413:81-91.
9. Crooke A., Huete-Toral F., Martínez-Águila A., Martín-Gil A., Pintor J. Involvement of carbonic anhydrases in the ocular hypotensive effect of melatonin analogue 5-MCA-NAT. J. Pineal Res. 2012, 52:265-270.
10. Curtis L.R., Garzon C.B., Arkoosh M., Collier T., Myers M.S., Buzitis J., Hahn M.E. Reduced cytochrome P4501A activity and recovery from oxidative stress during subchronic benzo[a]pyrene and benzo[e]pyrene treatment of rainbow trout. Toxicol. Appl. Pharmacol. 2011, 254:1-7.
11. Da Silva R.T., Hokoç J.N., De Mello F.G., Gardino P.F. Differential immunodetection of L-DOPA decarboxylase and tyrosine hydroxylase in the vertebrate retina. Int. J. Dev. Neurosci. 2009, 27:469-476.
12. Devavry S., Legros C., Brasseur C., Delagrange P., Spadoni G., Cohen W., Malpaux B., Boutin J.A., Nosjean O. Description of the constitutive activity of cloned human melatonin receptors hMT(1) and hMT(2) and discovery of inverse agonists. J. Pineal Res. 2012, 53(1):29-37.
13. Dubocovich M.L. Luzindole (N-0774): a novel melatonin receptor antagonist. J. Pharmacol. Exp. Ther. 1988, 246:902-910.
14. Dubocovich M.L., Delagrange P., Krause D.N., Sugden D., Cardinali D.P., Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol. Rev. 2010, 62:343-380.
15. Dutta K., Ghosh D., Nazmi A., Kumawat K.L., Basu A. A common carcinogen benzo[a]pyrene causes neuronal death in mouse via microglial activation. PLoS ONE 2010, 5(4):e9984.
16. Fu Y., Buryanovskyy L., Zhang Z. Quinone reductase 2 is a catechol quinone reductase. J. Biol. Chem. 2008, 283:23829-23835.
17. Gaikwad N.W., Yang L., Rogan E.G., Cavalieri E.L. Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones. Free Radic. Biol. Med. 2009, 46:253-262.
18. Gardino P.F., Dos Santos R.M., Hokoç J.N. Histogenesis and topographical distribution of tyrosine hydroxylase immunoreactive amacrine cells in the developing chick retina. Brain Res. Dev. Brain Res. 1993, 72:226-236.
19. He C., Wang C., Zhou Y., Li J., Zuo Z. Embryonic exposure to benzo(a)pyrene influences neural development and function in rockfish (Sebastiscus marmoratus). Neurotoxicology 2012, 33:758-762.
20. Johnson S., Persson Y., Frankki S., van Bavel B., Lundstedt S., Haglund P., Tysklind M. Degradation of polycyclic aromatic hydrocarbons (PAHs) in contaminated soils by Fenton's reagent: a multivariate evaluation of the importance of spoil characteristics and PAH properties. J. Hazard. Mater. 2007, 149:86-96.
21. Jockers R., Maurice P., Boutin J.A., Delagrange P. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?. Br. J. Pharmacol. 2008, 154:1182-1195.
22. Iskander K., Paquet M., Brayton C., Jaiswal A.K. Deficiency of NRH:quinone oxidoreductase 2 increases susceptibility to 7, 12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res. 2004, 64:5925-5928.
23. Kubrusly R.C., Guimarães M.Z., Vieira A.P., Hokoç J.N., Casarini D.E., De Mello M.C., De Mello F.G. L-DOPA supply to the neuro retina activates dopaminergic communication at the early stages of embryonic development. J. Neurochem. 2003, 86:45-54.
24. Lee B.M., Shim G.A. Dietary exposure estimation of benzo[a]pyrene and cancer risk assessment. J. Toxicol. Environ. Health A 2007, 70:1391-1394.
25. Li J., Wang Z., Cao J., Dong Y., Chen Y. Melatonin receptor subtypes Mel1a and Mel1c but not Mel1b are associated with monochromatic light-induced B-lymphocyte proliferation in broilers. Domest. Anim. Endocrinol. 2013, 45:206-215.
26. Lucarini S., Bedini A., Spadoni G., Piersanti G. An improved synthesis of cis-4-phenyl-2-propionamidotetralin (4-P-PDOT): a selective MT(2) melatonin receptor antagonist. Org. Biomol. Chem. 2008, 6:147-150.
27. Mailliet F., Ferry G., Vella F., Berger S., Cogé F., Chomarat P., Mallet C., Guénin S.P., Guillaumet G., Viaud-Massuard M.C., Yous S., Delagrange P., Boutin J.A. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem. Pharmacol. 2005, 71:74-88.
28. Markus R.P., Silva C.L., Franco D.G., Barbosa E.M.J., Ferreira Z.S. Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs?. Pharmacol. Ther. 2010, 126:251-262.
29. Molinari E.J., North P.C., Dubocovich M.L. 2-[125I]iodo-5-Methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites. Eur. J. Pharmacol. 1996, 301:159-168.
30. Nosjean O., Ferro M., Coge F., Beauverger P., Henlin J.M., Lefoulon F., Fauchere J.L., Delagrange P., Canet E., Boutin J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem. 2000, 275:31311-31317.
31. Nosjean O., Nicolas J.P., Klupsch F., Delagrange P., Canet E., Boutin J.A. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem. Pharmacol. 2001, 61:1369-1379.
32. Oxenkrug G.F., Bachurin S.O., Prakhie I.V., Zefirov N.S. Quinone reductase 2 and antidepressant effect of melatonin derivatives. Ann. N. Y. Acad. Sci. 2010, 1199:121-124.
33. Pegan S.D., Sturdy M., Ferry G., Delagrange P., Boutin J.A., Mesecar A.D. X-ray structural studies of quinone reductase 2 nanomolar range inhibitors. Protein Sci. 2011, 20:1182-1195.
34. Reddy P.V., Jensen K.C., Mesecar A.D., Fanwick P.E., Cushman M. Design, synthesis, and biological evaluation of potent quinoline and pyrroloquinoline ammosamide analogues as inhibitors of quinone reductase 2. J. Med. Chem. 2012, 55:367-377.
35. Reis R.A., Ventura A.L., Kubrusly R.C., de Mello M.C., de Mello F.G. Dopaminergic signaling in the developing retina. Brain Res. Rev. 2007, 54:181-188.
36. Reiter R.J., Tan D.X., Fuentes-Broto L. Melatonin: a multitasking molecule. Prog. Brain Res. 2010, 181:127-151.
37. Reybier K., Perio P., Ferry G., Bouajila J., Delagrange P., Boutin J.A., Nepveu F. Insights into the redox cycle of human quinone reductase 2. Free Radic. Res. 2011, 45:1184-1195.
38. Sampaio L.F.S., Hamassaki-Britto D.E., Markus R.P. Influence of melatonin on the development of functional nicotinic acetylcholine receptors in cultured chick retinal cells. Braz. J. Med. Biol. Res. 2005, 38:603-613.
39. Sampaio L.F.S. Melatonin inhibitory effect on cAMP accumulation in the chick retina development. Int. J. Dev. Neurosci. 2008, 26:277-282.
40. Sampaio L.F.S. An unexpected effect of 5-MCA-NAT in chick retinal development. Int. J. Dev. Neurosci. 2009, 27:511-515.
41. Sampaio L.F.S., Markus R.P. Melatonin and the time window for the expression of the alpha8 nicotinic acetylcholine receptor in the membrane of chick retinal cells in culture. Int. J. Dev. Neurosci. 2010, 28:245-249.
42. Sampaio L.F.S. Catecholquinones as substrates of the NRH:quinone oxidoreductase 2 in the brain and retina. Quinones: Occurrence, Medicinal Uses and Physiological Importance 2013, 141-156. NOVA Publishers, New York. S.C. Johnson, E.R. Price (Eds.).
43. Sampaio L.F.S. By receptors, binding sites or free radical scavenger action: is there a pivotal action mechanism for melatonin in retinal pathologies?. New Developments in Melatonin Research 2013, 193-204. NOVA Publishers, New York. D. Acuña-Castroviejo, I. Rusanova, G. Escames (Eds.).
44. Serle J.B., Wang R.F., Peterson W.M., Plourde R., Yerxa B.R. Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes. J. Glaucoma 2004, 13:385-388.
45. Slotkin T.A., Seidler F.J. Benzo[a]pyrene impairs neurodifferentiation in PC12 cells. Brain Res. Bull. 2009, 80:17-21.
46. Singh D.B., Gupta M.K., Singh D.V., Singh S.K., Misra K. Docking and in silicon ADMET studies of noraristeromycin, curcumin and its derivatives with plasmodium falciparum SAH hydrolase: a molecular drug target against malaria. Interdiscip. Sci. Comput. Life Sci. 2013, 5:1-12.
47. Suzen S. Melatonin and synthetic analogs as antioxidants. Curr. Drug Deliv. 2013, 10:71-75.
48. Tan D.X., Manchester L.C., Terron M.P., Flores L.J., Tamura H., Reiter R.J. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J. Pineal Res. 2007, 43:317-320.
49. Thomsen R., Christensen M.H. MolDock: a new technique for high-accuracy molecular docking. J. Med. Chem. 2006, 49:3315-3321.
50. Tosini G., Baba K., Hwang C.K., Iuvone P.M. Melatonin: an underappreciated player in retinal physiology and pathophysiology. Exp. Eye Res. 2012, 103:82-89.
51. Ventura A.L., Klein W.L., De Mello F.G. Differential ontogenesis of D1 and D2 dopaminergic receptors in the chick embryo retina. Brain Res. 1984, 314:217-223.
52. Vincent L., Cohen W., Delagrange P., Boutin J.A., Nosjean O. Molecular and cellular pharmacological properties of 5-methoxycarbonylamino N-acetyltryptamine (MCA-NAT): a nonspecific MT3 ligand. J. Pineal Res. 2010, 48:222-229.
53. Wormley D.D., Ramesh A., Hood D.B. Environmental contaminant mixture effects on CNS development, plasticity, and behavior. Toxicol. Appl. Pharmacol. 2004, 197:49-65.
54. Wood A.W., Levin W., Thakker D.R., Yagi H., Chang R.L., Ryan D.E., Thomas P.E., Dansette P.M., Whittaker N., Turujman S., Lehr R.E., Kumar S., Jerina D.M., Conney A.H. Biological activity of benzo[e]pyrene. An assessment based on mutagenic activities and metabolic profiles of the polycyclic hydrocarbon and its derivatives. J. Biol. Chem. 1979, 254:4408-4415.
55. Wiechmann A.F., Sherry D.M. Role of melatonin and its receptors in the vertebrate retina. Int. Rev. Cell Mol. Biol. 2013, 300:211-242.
56. Xia Y., Cheng S., He J., Liu X., Tang Y., Yuan H., He L., Lu T., Tu B., Wang Y. Effects of subchronic exposure to benzo[a]pyrene (B[a]P) on learning and memory, and neurotransmitters in male Sprague-Dawley rat. Neurotoxicology 2011, 32:188-198.
57. Zhao Q., Yang X.L., Holtzclaw W.D., Talalay P. Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase). Proc. Natl. Acad. Sci. U. S. A. 1997, 94:1669-1674.
58. Zmijewski M.A., Sweatman T.W., Slominski A.T. The melatonin-producing system is fully functional in retinal pigment epithelium (ARPE-19). Mol. Cell. Endocrinol. 2009, 307:211-216.